Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Targeting B cells in autoimmune diseases

Highly Accessed Review

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

John D Hainsworth

Author Affiliations

Sarah Cannon Cancer Center, Nashville, Tennessee, USA

Arthritis Res Ther 2003, 5(Suppl 4):S12-S16  doi:10.1186/ar1008

Published: 2 December 2003

Abstract

The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis (RA), via selective B lymphocyte depletion. Experience in oncology shows that rituximab is well tolerated in a variety of settings, with mild-to-moderate infusion related reactions following the first infusion being the most common adverse event. Current data suggest that the safety profile of rituximab in patients with RA is similar to that in oncology, but that the adverse events are less frequent and less severe in patients with RA.

Keywords:
B cell depletion; oncology; rheumatoid arthritis; rituximab; safety